Danielle Hammond

1.1k total citations
68 papers, 387 citations indexed

About

Danielle Hammond is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Danielle Hammond has authored 68 papers receiving a total of 387 indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Hematology, 30 papers in Genetics and 15 papers in Molecular Biology. Recurrent topics in Danielle Hammond's work include Acute Myeloid Leukemia Research (46 papers), Chronic Myeloid Leukemia Treatments (19 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (16 papers). Danielle Hammond is often cited by papers focused on Acute Myeloid Leukemia Research (46 papers), Chronic Myeloid Leukemia Treatments (19 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (16 papers). Danielle Hammond collaborates with scholars based in United States, Canada and United Kingdom. Danielle Hammond's co-authors include Naveen Pemmaraju, Courtney D. DiNardo, Marina Konopleva, Kelly S. Chien, Guillermo Garcia‐Manero, Simon Gilbody, Harland N. Sather, Christine Godfrey, Adele M. Hayes and David Richards and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PEDIATRICS.

In The Last Decade

Danielle Hammond

58 papers receiving 365 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Danielle Hammond United States	11	217	112	88	87	73	68	387
Ebba K. Lindqvist Sweden	11	199 0.9×	119 1.1×	28 0.3×	74 0.9×	101 1.4×	21	393
Adir Shaulov Israel	11	71 0.3×	73 0.7×	102 1.2×	51 0.6×	110 1.5×	50	299
Teresa Olivé Spain	9	75 0.3×	64 0.6×	89 1.0×	56 0.6×	40 0.5×	16	301
Blanca López‐Ibor Spain	11	72 0.3×	79 0.7×	111 1.3×	47 0.5×	34 0.5×	29	289
S Armitage United Kingdom	12	375 1.7×	62 0.6×	44 0.5×	149 1.7×	117 1.6×	23	570
Gail Megason United States	12	139 0.6×	82 0.7×	51 0.6×	148 1.7×	64 0.9×	34	425
S Simon United States	3	269 1.2×	134 1.2×	123 1.4×	42 0.5×	71 1.0×	4	438
Giuseppe Germanò Italy	11	111 0.5×	141 1.3×	86 1.0×	23 0.3×	39 0.5×	29	411
Matthew M. K. Shing Hong Kong	12	99 0.5×	32 0.3×	34 0.4×	124 1.4×	38 0.5×	28	314
Carl Philipp Schwarze Germany	9	260 1.2×	52 0.5×	83 0.9×	30 0.3×	106 1.5×	13	397

Countries citing papers authored by Danielle Hammond

Since Specialization

Citations

This map shows the geographic impact of Danielle Hammond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danielle Hammond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danielle Hammond more than expected).

Fields of papers citing papers by Danielle Hammond

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danielle Hammond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danielle Hammond. The network helps show where Danielle Hammond may publish in the future.

Co-authorship network of co-authors of Danielle Hammond

This figure shows the co-authorship network connecting the top 25 collaborators of Danielle Hammond. A scholar is included among the top collaborators of Danielle Hammond based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Danielle Hammond. Danielle Hammond is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Weeks, Lachelle D., Danielle Hammond, Sinisa Savic, et al.. (2025). Establishing a consensus definition of VEXAS flare for clinical research. Lara D. Veeken. 65(2).

Kantarjian, Hagop, Koji Sasaki, Nitin B. Jain, et al.. (2025). Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Blood. 146(Supplement 1). 1566–1566.

DiNardo, Courtney D., Kelly S. Chien, Danielle Hammond, et al.. (2025). A Phase 2 study of CPX‐351 in combination with venetoclax in patients with newly diagnosed high‐risk acute myeloid leukemia. HemaSphere. 9(10). e70214–e70214.

Chien, Kelly S., Ziyi Li, Kunhwa Kim, et al.. (2025). Outcomes of hypomethylating agent failure in patients with myelodysplastic syndromes. Blood. 146(Supplement 1). 2075–2075.

Kantarjian, Hagop M., Fadi Haddad, Nicholas J. Short, et al.. (2024). Early Predictors of Treatment-Free Remission in Chronic Myeloid Leukemia. Blood. 144(Supplement 1). 6605–6605. 1 indexed citations

Chien, Kelly S., Juan José Rodríguez‐Sevilla, Guillermo Montalban‐Bravo, et al.. (2024). A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure.. Journal of Clinical Oncology. 42(16_suppl). 6570–6570. 1 indexed citations

Bazinet, Alexandre, Ziyi Li, Juan José Rodríguez‐Sevilla, et al.. (2024). Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax. Clinical Cancer Research. 30(7). 1319–1326. 3 indexed citations

Bataller, Álex, Juan José Rodríguez‐Sevilla, Kelly S. Chien, et al.. (2024). NPM1‐mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage. Cancer. 130(20). 3452–3462.

Kantarjian, Hagop M., Musa Yılmaz, Guillermo Garcia‐Manero, et al.. (2024). A Phase II Study of Cladribine, Idarubicin, and Cytarabine (CLIA) in Combination with Gilteritinib for Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia. Blood. 144(Supplement 1). 2901–2901. 1 indexed citations

10.

Chien, Kelly S., Juan José Rodríguez‐Sevilla, Yesid Alvarado, et al.. (2024). A Phase I Study of the Myeloid Cell Leukemia 1 (MCL1) Inhibitor Tapotoclax (AMG 176) in Patients With Myelodysplastic Syndromes After Hypomethylating Agent (HMA) Failure. Clinical Lymphoma Myeloma & Leukemia. 24. S195–S195.

11.

DiNardo, Courtney D., Kelly S. Chien, Danielle Hammond, et al.. (2024). Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia. Blood. 144(Supplement 1). 1511–1511. 1 indexed citations

12.

Csizmar, Clifford M., Mark E. Gurney, Rashmi Kanagal‐Shamanna, et al.. (2024). Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML). Blood. 144(Supplement 1). 1820–1820. 1 indexed citations

13.

Hammond, Danielle, Kelly S. Chien, Abhishek Maiti, et al.. (2024). Interim Results of the Phase II Study Investigating CPX-351 in Combination with Ivosidenib for Patients with IDH1-Mutated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Blood. 144(Supplement 1). 4271–4271. 1 indexed citations

14.

Senapati, Jayastu, Sanam Loghavi, Nicholas J. Short, et al.. (2023). Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood. 142(19). 1647–1657. 35 indexed citations

15.

Montalban‐Bravo, Guillermo, Elias Jabbour, Gautam Borthakur, et al.. (2023). Phase 1/2 study of CPX ‐351 for patients with Int‐2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. British Journal of Haematology. 204(3). 898–909. 4 indexed citations

16.

Matsuo, Takahiro, Sebastian Wurster, Danielle Hammond, et al.. (2023). Invasive mucorales sinusitis in a young patient with Emberger syndrome and newly diagnosed AML: A case report and literature review of invasive fungal infections in GATA2 deficiency. Mycoses. 66(12). 1029–1034.

17.

Montalban‐Bravo, Guillermo, Elias Jabbour, Kelly S. Chien, et al.. (2023). Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms with FLT3 or CBL Mutations. Blood. 142(Supplement 1). 3238–3238. 1 indexed citations

18.

Hammond, Danielle, et al.. (2023). Clinical Uses of Inhaled Antifungals for Invasive Pulmonary Fungal Disease: Promises and Challenges. Journal of Fungi. 9(4). 464–464. 3 indexed citations

19.

Bazinet, Alexandre, Tapan M. Kadia, Sangeetha Venugopal, et al.. (2022). A retrospective study of cladribine and low‐dose cytarabine–based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. Cancer. 129(4). 560–568. 6 indexed citations

20.

Hammond, Danielle, Tapan M. Kadia, Courtney D. DiNardo, et al.. (2021). Clinical Characteristics and Contemporary Outcomes of Acute Myeloid Leukemia Evolving from Chronic Myelomonocytic Leukemia. Blood. 138(Supplement 1). 1224–1224. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact